Inhibitor Therapeutics (INTI) Assets (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Assets came in at $1.4 million in Q1 2026, down 68.18% YoY from $4.5 million in Q1 2025, and down 42.92% on a QoQ basis from $2.5 million in Q4 2025.
Inhibitor Therapeutics (INTI) Assets (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Assets data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Assets fell 68.18% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 68.18% YoY) and the FY2025 annual result came in at $2.5 million, down 55.9% from the prior year.
- Assets eased to $1.4 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Assets ranged from a high of $12.0 million in Q4 2022 to a low of $38517.0 in Q2 2022.
- A 5-year average of $5.5 million and a median of $5.7 million in 2024 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets plunged 71.79% — and 2023, when it surged 26273.64%.
- Tracing INTI's Assets over 5 years: stood at $12.0 million in 2022, then slipped by 25.27% to $8.9 million in 2023, then plunged by 36.37% to $5.7 million in 2024, then tumbled by 55.9% to $2.5 million in 2025, then slumped by 42.92% to $1.4 million in 2026.
- The last three Assets figures came in at $1.4 million (Q1 2026), $2.5 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 637,190.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.43 Mn |
| Dec 31, 2025 | 2.51 Mn |
| Sep 30, 2025 | 3.14 Mn |
| Jun 30, 2025 | 3.91 Mn |
| Mar 31, 2025 | 4.51 Mn |
| Dec 31, 2024 | 5.69 Mn |
| Sep 30, 2024 | 6.45 Mn |
| Jun 30, 2024 | 7.17 Mn |
| Mar 31, 2024 | 7.79 Mn |
| Dec 31, 2023 | 8.95 Mn |
| Sep 30, 2023 | 9.61 Mn |
| Jun 30, 2023 | 10.16 Mn |
| Mar 31, 2023 | 10.84 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | 63,117.00 |
| Jun 30, 2022 | 38,517.00 |
| Mar 31, 2022 | 61,143.00 |
| Dec 31, 2021 | 58,784.00 |
| Sep 30, 2021 | 92,518.00 |
| Jun 30, 2021 | 136,520.00 |